PROSPER
Prostate cancer: profiling and evaluation of ncRNA
| Coordinatore | TAMPEREEN YLIOPISTO
Organization address
address: Kalevantie 4 contact info |
| Nazionalità Coordinatore | Finland [FI] |
| Sito del progetto | http://www.uta.fi/imt/ProspeR/ |
| Totale costo | 3˙971˙688 € |
| EC contributo | 2˙986˙216 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-02-01 - 2012-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TAMPEREEN YLIOPISTO
Organization address
address: Kalevantie 4 contact info |
FI (TAMPERE) | coordinator | 0.00 |
| 2 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 0.00 |
| 3 |
EXIQON A/S
Organization address
address: Bygstubben 9 contact info |
DK (VEDBAEK) | participant | 0.00 |
| 4 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 0.00 |
| 5 |
ORION CORPORATION
Organization address
address: ORIONINTIE 1 contact info |
FI (ESPOO) | participant | 0.00 |
| 6 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 7 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 0.00 |
| 8 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Annually, over 200 000 new prostate cancer cases are diagnosed in Europe. This number is expected to further increase due to widespread use of prostate specific antigen (PSA) tests on asymptomatic men and an aging population. This leads to high rate of over-detection, where most cases will never experience cancer symptoms during their lifetime. Hence, our current lack of means to predict prostate cancer prognosis will have devastating impact on both life-quality and health care expenditures. Molecular mechanisms of the development of prostate cancer are largely unknown apart from the recognized role of androgens. Lack of knowledge on mechanisms leading to the development and progression of this cancer hampers development of efficacious prevention, specific diagnostics, prognostic, and therapeutic tools. Based on the emerging knowledge on the function of non-coding RNAs (ncRNAs) as regulators of key cellular mechanisms and our own preliminary data on expression of ncRNAs in prostate cancer, it is very likely that ncRNAs are involved in the tumorigenesis and progression of prostate cancer. Our planned studies of ncRNAs can contribute major breakthroughs to optimize individualized prostate cancer treatment by providing both novel biomarkers and drug targets. In this project, we will pursue two major clinical problems: 1) early identification of cases requiring aggressive curative treatment, and 2) develop efficient therapies against hormone-refractory prostate cancer. The project will cover all phases of translational research, from discovery to validation and implementation. We will identify novel ncRNAs, investigate their expression, genetic/epigenetic alterations, and function. We will develop diagnostic tools, identify and validate therapeutic targets. To assure the success of the project, our consortium consists of leading translational prostate cancer research centers in Europe and companies committed to develop ncRNA detection technologies and novel drugs.'
Descrizione progetto (Article)
Diagnosis of prostate cancer is largely based on testing positive for the prostate-specific antigen (PSA). This is increases the rate of over-detection without necessarily correlating with cancer symptoms.
Apart from the role of androgens in the development of prostate cancer, the effect of molecular mechanisms such as non-coding ribonucleic acids (ncRNAs) is unknown. The EU-funded 'Prostate cancer: Profiling and evaluation of ncRNA' (PROSPER) project proposed to explore the role of ncRNAs (regulators of key cellular mechanisms) in prostate cancer. Project members will also evaluate the potential use of ncRNAs in diagnostic and prognostic tools as well as therapy targets.
As a first step, scientists performed global microRNA (miRNA) expression analysis in prostate cancer samples, which led to the discovery of 20 novel miRNAs. Microarray analyses of miRNAs in over 180 prostate cancer samples indicated that androgens and/or the androgen receptor were instrumental in regulating expression of some miRNAs. Androgen signalling models verified the impact of androgen signalling on miRNA expression and also located androgen receptor binding sites near some of these miRNAs.
For prognostic and diagnostic purposes, http://www.uta.fi/ibt/institute/research/visakorpi/prosper.html (PROSPER) scientists identified a panel of 25 and 56 miRNAs, respectively, to distinguish between normal and prostate cancer samples. miRNAs with oncogenic or tumour suppressor activity in prostate cancer were also identified.
The prognostic and diagnostic miRNA panels developed during PROSPER could significantly improve the clinical diagnosis of prostate cancer and reduce unnecessary patient treatment. They also opened up new avenues for drug design and therapeutic exploitation.